The massive share issuance at a deep discount confirms severe capital needs for a pre-revenue biotech with a ~$47M market cap. Monitor for further dilution from the remaining 448M ordinary shares and ~1.3M ADR warrants yet to be issued. The stock faces persistent overhang from the massive option overhang (~2.1B options outstanding) and ongoing cash burn for Phase 3 trials.
Price Chart
Executive Summary
Radiopharm Theranostics filed a 6-K with the ASX to quote 384,493,800 new ordinary shares issued at AUD 0.015 per share, representing the underlying shares for 1,281,646 ADSs issued in a registered direct offering announced July 24, 2026. This filing mechanically completes the share quotation for the capital raise disclosed in the prior day's 424B5, which raised approximately $4.05M at a ~26% discount. The massive dilution—384M new shares on a base of ~3.5B pre-existing shares—is the key event, confirming the company's urgent need for cash to fund clinical programs for a pre-revenue biotech.
Key Facts
- 384,493,800 new ordinary shares quoted on ASX at AUD 0.015 per share, issued July 28, 2026
- Shares represent underlying for 1,281,646 ADSs issued in registered direct offering at $3.16/ADS (~26% discount to $4.29 close)
- Further securities yet to be issued: 448,839,531 ordinary shares, 448,839,531 options (exp. Jul 2029, ex $0.018), 64,082 ADR warrants (exp. Jul 2029, ex $3.95), and 1,281,646 ADR warrants (exp. Jul 2029, ex $3.79)
- Post-quotation issued capital: 3,928,709,960 ordinary shares quoted, plus ~2.1B options and ~400M unquoted options outstanding
- Cross-filing context: 424B5 filed 1 day prior raised ~$4.05M; combined with A$6.7M placement and A$6M SPP for ~$10M+ total raise
Financial Impact
Dilutive capital raise of ~$4.05M USD from ADS offering plus A$6.7M placement and up to A$6M SPP; 384M new shares issued at AUD 0.015 (~$0.01 USD), representing ~11% dilution to pre-existing ~3.5B share base
Risk Factors
- Further dilution from 448M additional ordinary shares and 1.3M ADR warrants yet to be issued
- Massive option overhang (~2.1B options) creates persistent selling pressure
- Pre-revenue biotech with urgent capital needs for registrational Phase 3 study
- 26% discount on ADS offering signals distressed financing conditions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-081991 |
| Document: ea0299472-6k_radiopharm.htm | 0001213900-26-081991 |
| Document: ea029947201ex99-2.htm | 0001213900-26-081991 |
| Document: 0001213900-26-081991-index-headers.html | 0001213900-26-081991 |
| Document: 0001213900-26-081991-index.html | 0001213900-26-081991 |
| Document: 0001213900-26-081991.txt | 0001213900-26-081991 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+5 | — | — |
Oct 20, 2026 6d ago | 6-K | $0.9900 | awaiting T+5 | — | $0.9600 (−3.03%) |
Oct 14, 2026 11d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9600 (−11.11%) |
Oct 5, 2026 21d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9600 (−24.41%) |
Oct 1, 2026 25d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9600 (−35.14%) |
Sep 30, 2026 26d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9600 (−40.74%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9600 (+38.93%) |
Sep 22, 2026 4w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9600 (−41.82%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9600 (−52.24%) |
Sep 11, 2026 6w ago | 6-K | $1.98 $1.65 | ▼ −16.67% | ▼ −16.45% | $0.9600 (−51.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers